Progress on the relationship between Siglec-15 and cancer immunotherapy
Objective To summarize the research progress of sialic acid-binding immunoglobulin-like lectin-15(Siglec-15)in the field of tumor immunity,in order to provide a new theoretical basis for tumor immunotherapy.Methods"Siglec-15,tumor,immunoregulation,signal pathway,immunotherapy"was used as the key words to systematically search the litera-ture published in China National Knowledge Infrastructure(CNKI)and PubMed database from 2013-01-01 to 2023-12-31.Inclu-sion criteria:(1)discovery and molecular characteristics of Siglec-15;(2)the mechanism of Siglec-15 in tumor immune regulation and related signaling pathways;(3)the prospect of Siglec-15 immunotherapy.Exclusion criteria:literature with low quality and obsolete data.A total of 51 articles were included for analysis.Results Existing research indicates that Siglec-15 is highly expressed in various tumor cells as well as tumor-associated macrophages(TAMs).It induces tumor immune evasion by suppressing the activation and proliferation of T cells.Additionally,Siglec-15 can regulate the tumor microenvironment by mediating specific molecular signal pathways.Currently,multiple Siglec-15-related drugs with anti-tumor activity are actively being developed,providing new avenues for tumor immunotherapy.Conclusion In recent years,with the emergence of resistance to programmed death-1(PD-1)and its ligand(PD-L1)antibodies,Siglec-15 is considered an emerging target that may serve as an alternative or synergistic approach to anti-PD-1/PD-L1 therapy,holding promise for significant contributions.
NETL
NSTL
万方数据
